<DOC>
	<DOC>NCT02448121</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow stem cells in sickle cell disease patients with hip osteonecrosis</brief_summary>
	<brief_title>Autologous Bone Marrow Stem Cell Transplantation for Hip Osteonecrosis in Sickle Cell Disease</brief_title>
	<detailed_description>The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for sickle cell disease patients with hip osteonecrosis.</detailed_description>
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<criteria>Stable sickle cell disease patients FICAT classification of osteonecrosis, inclusive of Stage II. Diagnosis will be based on XRay and magnetic resonance imaging (MRI). No infection in affected bones at the time of surgery. Patient competent to give informed consent. Scoring at least 20 points on the pain and daily life activities questionnaire. FICAT stage III or more Patients with a history of corticosteroids or on active therapy Bone infection at the limb affected by necrosis Recurrent painful crises, Immunosuppressive drug therapy, Pregnancy, Presence of neoplastic disease or any other clinical concurrent condition other than sickle cell disease that predisposed them to the development of osteonecrosis of the femoral head</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cell therapy</keyword>
	<keyword>Sickle cell disease</keyword>
	<keyword>Hip Osteonecrosis</keyword>
	<keyword>Autologous implantation</keyword>
	<keyword>Mesenchymal stromal cell</keyword>
</DOC>